Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

845 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Phase II study of cisplatin and vinorelbine as first-line chemotherapy in patients with carcinoma of the uterine cervix.
Pignata S, Silvestro G, Ferrari E, Selvaggi L, Perrone F, Maffeo A, Frezza P, Di Vagno G, Casella G, Ricchi P, Cormio G, Gallo C, Iodice F, Romeo F, Fiorentino R, Fortuna G, Tramontana S. Pignata S, et al. Among authors: gallo c. J Clin Oncol. 1999 Mar;17(3):756-60. doi: 10.1200/JCO.1999.17.3.756. J Clin Oncol. 1999. PMID: 10071263 Clinical Trial.
Carboplatin plus vinorelbine, a new well-tolerated and active regimen for the treatment of extensive-stage small-cell lung cancer: a phase II study. Gruppo Oncologico Centro-Sud-Isole.
Gridelli C, Perrone F, Ianniello GP, Brancaccio L, Iaffaioli RV, Curcio C, D'Aprile M, Cioffi R, Cigolari S, Rossi A, Palazzolo G, Veltri E, Pergola M, De Placido S, Gallo C, Monfardini S, Bianco AR. Gridelli C, et al. Among authors: gallo c. J Clin Oncol. 1998 Apr;16(4):1414-9. doi: 10.1200/JCO.1998.16.4.1414. J Clin Oncol. 1998. PMID: 9552045 Clinical Trial.
Mitomycin C plus vindesine plus etoposide (MEV) versus mitomycin C plus vindesine plus cisplatin (MVP) in stage IV non-small-cell lung cancer: A phase III multicentre randomised trial. The "Gruppo Oncologico Centro-Sud-Isole' (G.O.C.S.I.).
Gridelli C, Perrone F, Palmeri S, D'Aprile M, Cognetti F, Rossi A, Gebbia V, Pepe R, Veltri E, Airoma G, Russo A, Incoronato P, Scinto AF, Palazzolo G, Natali M, Leonardi V, Gallo C, De Placido S, Bianco AR. Gridelli C, et al. Among authors: gallo c. Ann Oncol. 1996 Oct;7(8):821-6. doi: 10.1093/oxfordjournals.annonc.a010761. Ann Oncol. 1996. PMID: 8922196 Free article. Clinical Trial.
Vinorelbine is well tolerated and active in the treatment of elderly patients with advanced non-small cell lung cancer. A two-stage phase II study.
Gridelli C, Perrone F, Gallo C, De Marinis F, Ianniello G, Cigolari S, Cariello S, Di Costanzo F, D'Aprile M, Rossi A, Migliorino R, Bartolucci R, Bianco AR, Pergola M, Monfardini S. Gridelli C, et al. Among authors: gallo c. Eur J Cancer. 1997 Mar;33(3):392-7. doi: 10.1016/s0959-8049(97)89011-9. Eur J Cancer. 1997. PMID: 9155522 Clinical Trial.
Gemcitabine plus vinorelbine in advanced non-small cell lung cancer: a phase II study of three different doses. Gem Vin Investigators.
Gridelli C, Frontini L, Perrone F, Gallo C, Gulisano M, Cigolari S, Castiglione F, Robbiati SF, Gasparini G, Ianniello GP, Farris A, Locatelli MC, Felletti R, Piazza E. Gridelli C, et al. Among authors: gallo c. Br J Cancer. 2000 Sep;83(6):707-14. doi: 10.1054/bjoc.2000.1341. Br J Cancer. 2000. PMID: 10952772 Free PMC article. Clinical Trial.
Activity and toxicity of gemcitabine and gemcitabine + vinorelbine in advanced non-small-cell lung cancer elderly patients: Phase II data from the Multicenter Italian Lung Cancer in the Elderly Study (MILES) randomized trial.
Gridelli C, Cigolari S, Gallo C, Manzione L, Ianniello GP, Frontini L, Ferraù F, Robbiati SF, Adamo V, Gasparini G, Novello S, Perrone F; MILES Investigators. Gridelli C, et al. Among authors: gallo c. Lung Cancer. 2001 Feb-Mar;31(2-3):277-84. doi: 10.1016/s0169-5002(00)00194-x. Lung Cancer. 2001. PMID: 11165408 Clinical Trial.
A multicentre phase II study of carboplatin plus pegylated liposomal doxorubicin as first-line chemotherapy for patients with advanced or recurrent endometrial carcinoma: the END-1 study of the MITO (Multicentre Italian Trials in Ovarian Cancer and Gynecologic Malignancies) group.
Pignata S, Scambia G, Pisano C, Breda E, Di Maio M, Greggi S, Ferrandina G, Lorusso D, Zagonel V, Febbraro A, Riva N, De Rosa V, Gallo C, Perrone F; Multicentre Italian Trials in Ovarian Cancer and Gynecologic Malignancies Group. Pignata S, et al. Among authors: gallo c. Br J Cancer. 2007 Jun 4;96(11):1639-43. doi: 10.1038/sj.bjc.6603787. Epub 2007 May 8. Br J Cancer. 2007. PMID: 17486128 Free PMC article. Clinical Trial.
845 results